FDA Approves Gilead’s COVID-19 Drug for Young Children


(Reuters) – The U.S. drug regulator on Monday granted the first full approval for treating COVID-19 in children aged 28 days and older to Gilead Sciences Inc’s drug remdesivir.

The move comes months after the agency expanded the drug’s emergency use authorization to also include children below 12 years of age weighing at least 3.5 kilograms.

The Food and Drug Administration’s (FDA) decision makes the drug the first approved COVID-19 treatment for children less than 12 years of age, the agency said.

The approval is applicable to children who are hospitalized, or have mild-to-moderate disease and are at high risk of severe COVID-19.

Articles You May Like

MRI-Based Screening May Detect Prostate Cancer Earlier
Sarepta Therapeutics Announces Update on Regulatory Review of SRP-9001
Stimulating a bile acid receptor can help protect the vision of premature newborns
RECOVER study: An important step toward defining long COVID
Are inadequate culinary skills among undergraduate students associated with obesity and overweight?

Leave a Reply

Your email address will not be published. Required fields are marked *